Cas-Br-M (Murine) Ecotropic Retroviral Transforming Sequence (CBL) (Tyr770) antibody

Antigen: Cas-Br-M (Murine) Ecotropic Retroviral Transforming Sequence (CBL)

Synonyms: cbl, Cbl-2, c-Cbl, 4732447J05Rik, CBL2, C-CBL, RNF55

Binding Site: Tyr770

Clonality: Monoclonal

Host: Mouse

Reactivity: Human

Conjugate: Un-conjugated

Application: Immunohistochemistry (IHC)

Certificates: ISO 9001:2008

Catalog no.: ABIN658935

Additional Information

Alternative name: C-Cbl

Gene ID: 867

UniProt: P22681

Isotype: IgG

Description: Other names: RING finger protein 55, Casitas B-lineage lymphoma proto-oncogene, Proto-oncogene c-Cbl, Signal transduction protein CBL, E3 ubiquitin-protein ligase CBL

Characteristics: Purified Rabbit Polyclonal Antibody (Pab)

Specificity: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

Molecular Weight: 99633 DA

Comments:

Background: The cbl oncogene was first identified as part of a transforming retrovirus which induces mouse pre-B and pro-B cell lymphomas. As an adaptor protein for receptor protein-tyrosine kinases, it positively regulates receptor protein-tyrosine kinase ubiquitination in a manner dependent upon its variant SH2 and RING finger domains. Ubiquitination of receptor protein-tyrosine kinases terminates signaling by marking active receptors for degradation.

Application Details

Application Notes: The suggested dilution is: IHC: 1:50-1:100

Concentration: 1mg/ml

Purification: Purified

Buffer: affinity Purified IgG, in PBS, 0.02% sodium azide and 50% glycerol.

Storage: Maintain refrigerated at 2-8 deg C for up to 6 months. For long term storage store at -20 deg C in small aliquots to prevent freeze-thaw cycles

Research Area: Signaling, Phospho-specific antibodies, Protein Modifications, Cancer, Cell Structure

Restrictions: For Research Use only

Publications

Product: Ye, Cihil, Stolz et al.: "c-Cbl facilitates endocytosis and lysosomal degradation of cystic fibrosis transmembrane conductance regulator in human airway epithelial cells." in: The Journal of biological chemistry, Vol. 285, Issue 35, pp. 27008-18, 2010 (PubMed).

Matsuda, Taira, Sakashita et al.: "Long-term survival after nonintensive chemotherapy in some juvenile myelomonocytic leukemia patients with CBL mutations, and the possible presence of healthy persons with the mutations." in: Blood, Vol. 115, Issue 26, pp. 5429-31, 2010 (PubMed).

Martinelli, De Luca, Stellacci et al.: "Heterozygous germline mutations in the CBL tumor-suppressor gene cause a Noonan syndrome-like phenotype." in: American journal of human genetics, Vol. 87, Issue 2, pp. 250-7, 2010 (PubMed).

Rocquain, Carbuccia, Trouplin et al.: "Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias." in: BMC cancer, Vol. 10, pp. 401, 2010 (PubMed).

Niemeyer, Kang, Shin et al.: "Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia." in: Nature genetics, Vol. 42, Issue 9, pp. 794-800, 2010 (PubMed).